Redox Biology · 2014 · 36 citations · 22 references
Life SciencesCardiologyPhysiologyMetabolic PhysiologyMetabolic RegulationMitochondrial BiologyCardiac PhysiologyCardiovascular PhysiologyMitochondrial DysfunctionMitochondrial MetabolismMitochondrial PhysiologyPulmonary HypertensionCardiac Mitochondrial FunctionCardiac Systolic FunctionCoenzyme Q MetabolismHemoglobin Heme SynthesisMetabolic ModulationMetabolic TherapiesMitochondrial Heme SynthesisSupplement Dosage
Mitochondrial dysfunction is a fundamental abnormality in the vascular endothelium and smooth muscle of patients with pulmonary arterial hypertension (PAH). Because coenzyme Q (CoQ) is essential for mitochondrial function and efficient oxygen utilization as the electron carrier in the inner mitochondrial membrane, we hypothesized that CoQ would improve mitochondrial function and benefit PAH patients. To test this, oxidized and reduced levels of CoQ, cardiac function by echocardiogram, mitochondrial functions of heme synthesis and cellular metabolism were evaluated in PAH patients (N=8) in comparison to healthy controls (N=7), at baseline and after 12 weeks oral CoQ supplementation. CoQ levels were similar among PAH and control individuals, and increased in all subjects with CoQ supplementation. PAH patients had higher CoQ levels than controls with supplementation, and a tendency to a higher reduced-to-oxidized CoQ ratio. Cardiac parameters improved with CoQ supplementation, although 6-minute walk distances and BNP levels did not significantly change. Consistent with improved mitochondrial synthetic function, hemoglobin increased and red cell distribution width (RDW) decreased in PAH patients with CoQ, while hemoglobin declined slightly and RDW did not change in healthy controls. In contrast, metabolic and redox parameters, including lactate, pyruvate and reduced or oxidized gluthathione, did not change in PAH patients with CoQ. In summary, CoQ improved hemoglobin and red cell maturation in PAH, but longer studies and/or higher doses with a randomized placebo-controlled controlled design are necessary to evaluate the clinical benefit of this simple nutritional supplement.
22
Roberto M. Lang, Michelle Bierig, Richard B. Devereux et al. · Journal of the American Society of Echocardiography · 2005 · 11.3K citations
Lawrence Rudski, Wyman W. Lai, Jonathan Afilalo et al. · Journal of the American Society of Echocardiography · 2010 · 7K citations · Full text
Superoxide activates mitochondrial uncoupling proteins
Karim S. Echtay, Damien Roussel, Julie St‐Pierre et al. · Nature · 2002 · 1.4K citations
Sébastien Bonnet, Evangelos D. Michelakis, Christopher J. Porter et al. · Circulation · 2006 · 583 citations
Epigenetic Attenuation of Mitochondrial Superoxide Dismutase 2 in Pulmonary Arterial Hypertension
Stephen L. Archer, Glenn Marsboom, Gene Kim et al. · Circulation · 2010 · 407 citations · Full text